Viewing Study NCT05286957


Ignite Creation Date: 2025-12-24 @ 6:47 PM
Ignite Modification Date: 2026-01-04 @ 2:06 AM
Study NCT ID: NCT05286957
Status: RECRUITING
Last Update Posted: 2023-03-17
First Post: 2022-03-01
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
Sponsor: The First Affiliated Hospital of Zhengzhou University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module